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A recent meta-analysis and meta-regression of 13 randomized clinical trials by Mocking et al.1 
concluded that supplementation with omega-3 fatty acids, found naturally in fatty fish, has a 
beneficial effect in patients with Major Depressive Disorder (MDD), especially for higher doses of the 
acid EPA and in patients taking antidepressants. Novel treatments for MDD are certainly desired. 
However, in our view the evidence in this study does not solve the academic debate on the efficacy 
of omega-3 fatty acids for MDD. Some food for thought.  
 
Meta-analysis: not more than the sum of its parts 
Based on the widely-accepted GRADE system, a recent Cochrane review evaluated the overall 
quality of the evidence of studies on omega-3 fatty acids and depressive symptomatology (n=26) as 
very low,2 and the body of evidence as composed of a limited number of predominantly small 
studies at high risk of selection, performance, or attrition bias. Poor evidence-quality downgrades 
the credibility of overall effect size estimates, particularly when the evidence for an effect appears to 
be driven by poorer quality studies.  
Study selection concerns aside, Mocking et al.1 found no association between study effect 
size and study quality as operationalized by the 5-point Jadad score in their subset of 13 studies. 
Jadad scores, however, simply indicate whether a study reports a double blind randomized trial and 
reports drop-outs and withdrawals, resulting in a maximal score for 9 of the 13 reviewed studies. 
This minimal variation largely reduced the power to detect associations with study effect size. More 
importantly, the Jadad score ignores highly relevant aspects such as risk of bias and study precision 
(1/standard error). Analyses conducted on studies with low risk of bias have consistently produced 
non-significant effect estimates.2 Moreover, based on the mean standardized differences and 
standard errors reported in their Figure 1, we found that the studies included in Mocking et al.1 
show an inverse association between study effect size and study precision (r = -0.344): less precise 
trials produced larger effect sizes. To illustrate the impact less precise studies can have on meta-
analytic results, we repeated the meta-analysis (based on the data provided in Mocking et al.1) but 
 
 
 
 
without the least precise study3 (N=20), which reduced the overall effect size from SMD = 0.398 
(95% CI: 0.114, 0.681, p = .006) to 0.317 (95% CI: 0.051, 0.582, p = .019). Additionally excluding the 
second-least precise study4 (N=22) further reduces the effect size to 0.227 (95% CIs: 0.001, 0.453, p = 
.049). Thus, the observed effect of omega-3 fatty acid supplementation on depression is largely 
driven by the most imprecise studies.  
 
Meta-regression: the more trials the merrier  
Based on 9 univariate meta-regressions (one for each study characteristic) across 13 trials, Mocking 
et al.1 concluded that omega-3 fatty acid supplementation in MDD patients is especially beneficial in 
patients using antidepressants and for higher doses of EPA. The low number of trials reduces the 
probability of a true negative finding: when high heterogeneity is present across studies, as is the 
case in Mocking et al.1 (I2 = 73%, t2 = 0.171), power of 80% to detect even the largest of the modest 
moderator effects reported in Mocking et al.1 cannot be achieved except with a much larger number 
of trials (k > 200)5. Perhaps counter-intuitively, low statistical power also decreases the probability 
that an observed effect that reaches nominal statistical significance actually reflects a true effect6,7. 
The risk of false positive findings is further increased by the substantial number of statistical tests 
conducted in this study.7,8 Indeed, neither of the results (antidepressants, p =.044; EPA dose, p = 
.009) survives correction for multiple comparisons (Bonferroni p-value = 0.05/9 = .006), and the EPA 
dose-response relationship is mainly attributable to the two least precise studies3,4 (Figure 1).  
 
[insert Figure 1 here] 
 
Meta-regression: correlation is not causation 
The conclusions on EPA dose and antidepressant use were not based on randomization of these 
characteristics. Meta-regression is observational and therefore susceptible to confounding; it does 
not allow causal inference.8 Hence, the associations found with EPA dose and antidepressant use 
could be due to other, known or unknown, trial characteristics. That findings from this meta-
regression do not necessarily align with results from intervention studies is illustrated by the largest 
clinical trial available to date (N = 432)9, which stratified randomization by antidepressant use and 
found evidence for neither an interaction between treatment group and antidepressant use, nor 
benefit from EPA supplementation among the subgroup of patients also taking antidepressants 
(n=174).  
 
Meta-analyses are critical to evidence-based medicine, but may lead to biased conclusions if the 
quality of available evidence is not adequately considered. Findings from meta-regression should be 
interpreted with particular caution, especially when suggesting clinical implications. Even if 
unbiased, a statistically significant result is not necessarily clinically relevant, and one may wonder 
whether, for instance, a decrease of 0.04 on the 17-item Hamilton Depression Rating Scale with 
every 100 mg increase in EPA dose is meaningful. In our view, the current evidence supporting the 
use of omega-3 fatty acid supplementation in depression remains weak and clinical implications 
should be tempered.  
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Figure Legend 
 
Figure 1 Dose-response relationship. Circles represent the effect size of the individual trials scaled by their 
sample size. The grey circles represent the studies by Nemets et al. 3 and Su et al.4 (top right), which have the 
smallest sample sizes and the largest effect sizes. The dose-response relationship is depicted as a solid line for 
the linear trend based on all trials (r = 0.6) and a grey line discarding Nemets et al.3 and Su et al.4 (r = 0.1).  
 
 
 
 
 

